Navigation Links
Radioimmunotherapy After Chemo Safe for Common Lymphoma
Date:3/13/2008

Combo treatment improved overall survival rates in follicular non-Hodgkin lymphoma

THURSDAY, March 13 (HealthDay News) -- Radioimmunotherapy after chemotherapy is safe and effective for patients with follicular non-Hodgkin lymphoma (NHL), according to an Italian study.

It found that radioimmunotherapy with the radioactive drug yttrium-90 (90Y) ibritumombab tiuxetan, following chemotherapy with fludarabine and mitoxantrone is feasible, well-tolerated and effective in follicular NHL patients.

The study began with 61 patients who received six cycles of oral fludarabine and intravenous mitoxantrone. Of these, 57 (43 with complete response and 14 with partial response) were deemed eligible for subsequent radioimmunotherapy with 90Y- ibritumombab tiuxetan. After that treatment, 12 of the 14 partial response patients achieved complete response.

At a median follow-up of 30 months, three-year progression-free survival among the 57 patients was 76 percent, and three-year overall survival was 100 percent. Grade 3 or 4 hematological effects were noted in 36 of the 57 patients.

"This study has established the feasibility, tolerability, and efficacy of sequential treatment with six cycles of fludarabine and mitoxantrone chemotherapy followed by 90Y- ibritumombab tiuxetan as a front-line treatment for untreated patients with follicular NHL. In particular, the data represent the first evidence of a role of 90Y- ibritumombab tiuxetan after a fludarabine-containing regimen in the treatment of follicular NHL," the study authors concluded.

The findings were published online this week in The Lancet Oncology, and were expected to be published in the April print edition of the journal.

Follicular NHL -- the most common form of lymphoma in Europe and the United States -- accounts for about 30 percent of all newly diagnosed NHLs.

More information

The Lymphoma Research Foundation outlines common forms of lymphoma.



-- Robert Preidt



SOURCE: The Lancet, news release, March 12, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Work-Family Conflict Dogs Air Force Women After Deployment
2. Work-Family Conflict Dogs Air Force Women After Deployment
3. Stopping Statins After Stroke Doubles Death Risk
4. Billy Graham Home After Hospitalization:
5. Swelling After Knee Injury May Hinder Healing
6. Going on After Loss
7. Discover The Mutter Museum After Dark
8. Cialis Eases Erectile Dysfunction After Spinal Cord Injury
9. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
10. Vitamin Relief Brings Needed Nutrition to School District Resurrecting After Katrina
11. Pill Equals Injection in Preventing Clots After Hip Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Radioimmunotherapy After Chemo Safe for Common Lymphoma
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... 52" report to their offering. ... creates a favourable commercial environment for MedImmune to enter. The ... that will serve to drive considerable growth for effective anti-influenza ... to cap sales considerably, but development is still in its ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology: